– Reuters Citing Blog
Deutsche Bank Maintains Buy on MKS Instruments, Lowers Price Target to $125
Deutsche Bank analyst Sidney Ho maintains MKS Instruments (NASDAQ:MKSI) with a Buy and lowers the price target from $150 to $125.
Related Posts
Tempest Therapeutics Q4 EPS $(0.63) Beats $(0.76) Estimate
Tempest Therapeutics (NASDAQ:TPST) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.76) by 17.11 percent. This is a 3250 percent decrease over earnings of $0.02 per share
What’s Going On With Palantir’s Stock?
Palantir's first-quarter revenue increased 21% year-over-year to $634 million, beating the consensus estimate. However, the stock tumbled as investors reacted negatively to the company's light guidance for the second quarter and the full year. CNBC's Jim Cramer said he still believes Palantir is a strong company following the earnings report. "I like that conference call very, very much," Cramer said. "I say not to worry, that company is a good company to own right here, right now."
Glow Preparing To Launch Multiple In-House Cannabis Consumer Brands
Glow LifeTech Corp. (OTCPK:GLWLF) (CSE:GLOW) (FSE:9DO) announced the upcoming launch of multiple in-house cannabis consumer brands powered by its portfolio of proprietary ingredient technologies. The company expects to commercially deploy its products into the Canadian cannabis market as early as Q3 2023.